# A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

> **NCT05919693** · PHASE1,PHASE2 · COMPLETED · sponsor: **EyeBiotech Ltd.** · enrollment: 33 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration (NVAMD)
- Diabetic Macular Edema (DME)

## Interventions

- **DRUG:** EYE103

## Key facts

- **NCT ID:** NCT05919693
- **Lead sponsor:** EyeBiotech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-12
- **Primary completion:** 2024-08-26
- **Final completion:** 2024-08-26
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05919693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05919693, "A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05919693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*